skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Alterations in locomotor activity induced by radioprotective doses of 16,16-dimethyl prostaglandin E2

Technical Report ·
OSTI ID:6994238

16,16-Dimethyl prostaglandin E2 (DiPGE2) is an effective radioprotectant when administered before irradiation. A notable side effect of this compound is sedation. In separate experiments, the dose-response determinations of the time course of locomotor activity and 30-day survival after 10 Gy gamma irradiation (LD100) were made. Adult male CD2F1 mice were injected subcutaneously with vehicle or DiPGE2 in doses ranging from 0.01 to 40 micrograms per mouse. A dose of 0.01 micrograms did not result in alterations in locomotor behaviour or enhance survival. Doses greater than 1 microgram produced ataxia and enhanced radiation survival in a dose-dependent fashion. Full recovery of locomotor activity did not occur until 6 and 30 hr after injection for the 10 microgram and 40 microgram groups, respectively. Radioprotection was observed when DiPGE2 was administered preirradiation but not postirradiation. Doses of 1 and 10 micrograms were maximally effective as a radioprotectant if injected 5 min prior to irradiation (80%-90% survival). A dose of 40 micrograms resulted in 100% survival when injected 5-30 min before irradiation. Therefore, increasing doses of DiPGE2 resulted in an enhanced effectiveness as a radioprotectant. However, the doses that were the most radioprotective were also the most debilitating to the animal.

Research Organization:
Armed Forces Radiobiology Research Inst., Bethesda, MD (USA)
OSTI ID:
6994238
Report Number(s):
AD-A-192637/7/XAB; AFRRI-SR-87-40
Resource Relation:
Other Information: Pub. in Prostaglandin and Lipid Matabolism in Radiation Injury, 245-251(1987)
Country of Publication:
United States
Language:
English